• slideshow1
  • slideshow1
  • slideshow1
  • slideshow1

Innovative biopharmaceutical company, Fab'entech has been specialising for already 5 years in the treatment of emergent infectious diseases.

The rapid emergence of viral diseases such as avian influenza and hemorrhagic fever is creating new pandemic risks. The development of emergency therapies to help infected patients get through the critical stage and help reduce the spread of infection are urgently needed.

To address these public health threats, Fab’entech has developed anti-infective passive immunotherapy solutions, which are based on highly purified specific polyclonal antibodies. Once administered to patients, antibodies specifically and immediately neutralize circulating viruses and hamper the development of the disease.

INFLUENZA
To date, Fab'entech has already developed a first treatment against avian influenza H5N1 virus.
EBOLA
In the present context, Fab’entech is evaluating with international health authorities and other partners the potential development of a treatment against Ebola virus.
 

Partners

Sanofi Pasteur - INSERM Jean Mérieux BSL-4 Laboratory (Lyon) - LyonBiopôle - Greater Lyon - Bpifrance...  Read more

  • Last news
  • DGA Innovation forum
  • Fab'entech at the DGA Innovation forum in the Polytechnique School ... Read more
  • Certificate of GMP compliance
  • Certificate of GMP compliance for Fab'entech... Read more
  • Orphan medicinal product designation for FBF-001 (anti-H5N1)
  • Committee for Orphan Medicinal Products (COMP) meeting report.... Read more